Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study

被引:90
作者
Akizawa, Tadao [1 ]
Otsuka, Tetsuro [2 ]
Reusch, Michael [3 ]
Ueno, Mai [2 ]
机构
[1] Showa Univ, Sch Med, Tokyo, Japan
[2] Astellas Pharma Inc, Tokyo, Japan
[3] Astellas Pharma Europe BV, Leiden, Netherlands
关键词
Anemia; Chronic kidney disease; Clinical trial; Peritoneal dialysis; Roxadustat; FG-4592; SAFETY;
D O I
10.1111/1744-9987.12888
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open-label, 24-week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal dialysis (PD) who were previously treated or not treated with erythropoiesis stimulating agents (ESAs). Patients not previously receiving ESA (ESA-Naive group) were randomized to roxadustat at a starting dose of 50 or 70 mg three times weekly; patients previously receiving ESA (ESA-Converted group) switched from ESA to roxadustat 70 or 100 mg three times weekly depending on the prior ESA dose. Outcomes included maintenance rate of average hemoglobin (Hb) level within 10-12 g/dL at weeks 18-24, cumulative response rate at end of treatment (Hb thresholds, 10.0 g/dL or 10.5 g/dL; Hb increase, >= 1.0 g/dL), and average Hb levels at weeks 18-24. Safety was assessed by occurrence of treatment-emergent adverse events (TEAEs). Fifty-six patients were enrolled (ESA-Naive, n = 13; ESA-Converted, n = 43). Maintenance rates (weeks 18-24) were 92.3% (95% CI: 64.0-99.8; ESA-Naive) and 74.4% (95% CI: 58.8-86.5; ESA-Converted). Cumulative response rate was 100.0% in the ESA-Naive group. Average Hb levels (weeks 18-24) were 11.05 g/dL (95% CI: 10.67-11.42; ESA-Naive) and 10.93 g/dL (95% CI: 10.73-11.13; ESA-Converted). Common TEAEs included nasopharyngitis and back pain. Roxadustat was well tolerated and effective in maintaining target Hb levels in CKD patients on PD who were previously treated or not treated with ESA.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 16 条
[1]   Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review [J].
Akizawa, Tadao ;
Okumura, Hiroyuki ;
Alexandre, Ana Filipa ;
Fukushima, Ayako ;
Kiyabu, Grace ;
Dorey, Julie .
THERAPEUTIC APHERESIS AND DIALYSIS, 2018, 22 (05) :444-456
[2]   Mechanisms of Anemia in CKD [J].
Babitt, Jodie L. ;
Lin, Herbert Y. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (10) :1631-1634
[3]   Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients [J].
Besarab, Anatole ;
Chernyayskaya, Elena ;
Motylev, Igor ;
Shutov, Evgeny ;
Kumbar, Lalathaksha M. ;
Gurevich, Konstantin ;
Chan, Daniel Tak Mao ;
Leong, Robert ;
Poole, Lona ;
Zhong, Ming ;
Saikali, Khalil G. ;
Franco, Marietta ;
Hemmerich, Stefan ;
Kin-Hung Peony Yu ;
Neff, Thomas B. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (04) :1225-1233
[4]   Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients [J].
Besarab, Anatole ;
Provenzano, Robert ;
Hertel, Joachim ;
Zabaneh, Raja ;
Klaus, Stephen J. ;
Lee, Tyson ;
Leong, Robert ;
Hemmerich, Stefan ;
Yu, Kin-Hung Peony ;
Neff, Thomas B. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (10) :1665-1673
[5]   Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China [J].
Chen, Nan ;
Qian, Jiaqi ;
Chen, Jianghua ;
Yu, Xueqing ;
Mei, Changlin ;
Hao, Chuanming ;
Jiang, Gengru ;
Lin, Hongli ;
Zhang, Xinzhou ;
Zuo, Li ;
He, Qiang ;
Fu, Ping ;
Li, Xuemei ;
Ni, Dalvin ;
Hemmerich, Stefan ;
Liu, Cameron ;
Szczech, Lynda ;
Besarab, Anatole ;
Neff, Thomas B. ;
Yu, Kin-Hung Peony ;
Valone, Frank H. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (08) :1373-1386
[6]   An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease [J].
Del Vecchio, Lucia ;
Locatelli, Francesco .
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) :1021-1030
[7]  
Del Vecchio L, 2012, CONTRIB NEPHROL, V178, P89, DOI 10.1159/000337818
[8]   Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation [J].
Ganz, T .
BLOOD, 2003, 102 (03) :783-788
[9]  
Krediet RT, 2017, NETH J MED, V75, P179
[10]   Changes in the worldwide epidemiology of peritoneal dialysis [J].
Li, Philip Kam-Tao ;
Chow, Kai Ming ;
Van de Luijtgaarden, Moniek W. M. ;
Johnson, David W. ;
Jager, Kitty J. ;
Mehrotra, Rajnish ;
Naicker, Sarala ;
Pecoits-Filho, Roberto ;
Yu, Xue Qing ;
Lameire, Norbert .
NATURE REVIEWS NEPHROLOGY, 2017, 13 (02) :90-103